ArticleBMC cardiovascular disorders2026
Correlation between Chinese visceral adiposity index and incidence of hypertension across different blood pressure status: a cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension is a significant global public health issue and its pathogenesis is strongly associated with visceral obesity. The Chinese Visceral Adiposity Index (CVAI), a well-established indicator based on the metabolic profile of Asian populations, has been linked to an increased risk of hypertension. However, there is a lack of comprehensive evidence regarding the differential relationship between the CVAI and the incidence of hypertension in participants with normal vs. elevated blood pressure (BP). This study aimed to utilize longitudinal data to examine the association between the CVAI and the incidence of hypertension across populations with different baseline BP levels.
methodsData from the China Health and Retirement Longitudinal Study (CHARLS) database were used for this retrospective cohort analysis. Participants aged ≥45 years without hypertension at baseline (2011) were included and followed up until 2020 to assess the incidence of hypertension. The CVAI was calculated using a sex-specific formula incorporating age, waist circumference (WC), body mass index (BMI), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C). Multivariate logistic regression and restricted cubic spline (RCS) models were used to evaluate the nonlinear association between CVAI and hypertension risk. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive ability of CVAI. For the sensitivity analyses, univariate RCS models were employed to assess the robustness of the findings.
resultsAmong 5311 participants, 1,819 (34.25%) developed hypertension during the 9-year follow-up period. CVAI emerged as an independent risk factor for incident hypertension. Comparing the highest to the lowest quartile of CVAI, the adjusted odds ratio (OR) was 1.77 (95% CI: 1.32-2.38) in the normal BP group and 3.21 (95% CI: 2.26-4.61) in the elevated BP group.
conclusionsA linear dose-response relationship was observed between CVAI and hypertension risk in both groups. These associations remained robust and linear in sensitivity analyses after excluding participants with diabetes, heart disease, or stroke. Clinically, CVAI offers a simple, low-cost tool to improve hypertension risk stratification and enable earlier targeted prevention, particularly among individuals with elevated BP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.